Written by : Dr. Aishwarya Sarthe
January 23, 2025
The funding will bolster Prantae’s efforts to launch diagnostic tools to address chronic kidney disease (CKD) and diabetes, further enhancing its portfolio of patient-focused solutions.
Prantae Solutions, a deep-tech company focused on innovative diagnostics, has raised INR 5 Cr in a seed funding round led by the Indian Angel Network (IAN) Group, with contributions from IAN Alpha Fund and individual investors Samir Kalia, Deepank Kumar, and Nitin Zamre.
The funding will bolster Prantae’s efforts to launch diagnostic tools to address chronic kidney disease (CKD) and diabetes, further enhancing its portfolio of patient-focused solutions.
Speaking on the development, Sumona Karjee Mishra, Chairman and Managing Director of Prantae Solutions, said, “With the invaluable support of Indian Angel Network, we are empowered to accelerate our journey toward transforming healthcare. This investment fuels our vision to deliver world-class point-of-care diagnostics with our flagship product, Proflo-U, and champion early detection and personalized kidney care. Together, we are creating a future where innovation meets compassion, redefining health outcomes for communities everywhere.”
The Bhubaneswar-based firm specializes in point-of-care diagnostic tools that address major health issues such as CKD and preeclampsia. With a strong emphasis on research and development, Prantae aims to advance healthcare accessibility and affordability.
The company’s flagship product, Proflo-U, is designed to offer quick and accurate kidney health assessments. It employs proprietary nanosensors, the Internet of Things (IoT), and artificial intelligence (AI) to deliver calibration-free, cost-effective testing solutions.
Highlighting its capability, the device measures microalbumin to proteinuria levels with unmatched accuracy, helping healthcare providers ensure early intervention for kidney conditions.
Padmaja Ruparel, Co-founder of the IAN Group, expressed optimism about Prantae’s potential, said, “Prantae Solutions is a stellar example of how deep-tech innovations can address critical healthcare challenges, especially in underserved markets. Their transformative diagnostic tools have the potential to make healthcare more inclusive and accessible, not just in India but globally. We are proud to back a team that combines exceptional innovation with a deeply personal mission to create meaningful impact.”
The origins of Prantae Solutions are deeply personal, stemming from the founders’ experiences. Sumona and her husband, Aseem, established the company in 2015 after encountering a life-threatening situation due to a lack of early diagnostic tools for preeclampsia. Their shared passion for deep-tech solutions and biotechnology has fueled their mission to bridge diagnostic gaps in healthcare.
CKD, a global health issue affecting over 700 million people, remains a key focus for Prantae. The company’s efforts align with the growing demand for accessible diagnostics in India, where the point-of-care market is projected to grow from $1.41 billion in FY2024 to $ 2.71 billion by FY2032.